Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


Articles published in Oncogene

Retrieve available abstracts of 68 articles:
HTML format
Text format



Single Articles


    April 2019
  1. GHOSHAL A, Rodrigues LC, Gowda CP, Elcheva IA, et al
    Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis.
    Oncogene. 2019 Apr 1. pii: 10.1038/s41388-019-0797.
    PubMed     Text format     Abstract available


  2. GE X, Li GY, Jiang L, Jia L, et al
    Long noncoding RNA CAR10 promotes lung adenocarcinoma metastasis via miR-203/30/SNAI axis.
    Oncogene. 2019;38:3061-3076.
    PubMed     Text format     Abstract available


    February 2019
  3. PEROTTI V, Baldassari P, Molla A, Nicolini G, et al
    An actionable axis linking NFATc2 to EZH2 controls the EMT-like program of melanoma cells.
    Oncogene. 2019 Feb 1. pii: 10.1038/s41388-019-0729.
    PubMed     Text format     Abstract available


  4. LUBRANO S, Comelli L, Piccirilli C, Marranci A, et al
    Development of a yeast-based system to identify new hBRAFV600E functional interactors.
    Oncogene. 2019;38:1355-1366.
    PubMed     Text format     Abstract available


    January 2019
  5. PEROTTI V, Baldassari P, Molla A, Vegetti C, et al
    Correction to: NFATc2 is an intrinsic regulator of melanoma dedifferentiation.
    Oncogene. 2019 Jan 28. pii: 10.1038/s41388-019-0679.
    PubMed     Text format     Abstract available


  6. EL KHARBILI M, Agaesse G, Barbollat-Boutrand L, Pommier RM, et al
    Tspan8-beta-catenin positive feedback loop promotes melanoma invasion.
    Oncogene. 2019 Jan 24. pii: 10.1038/s41388-019-0691.
    PubMed     Text format     Abstract available


  7. MANCUSO P, Tricarico R, Bhattacharjee V, Cosentino L, et al
    Thymine DNA glycosylase as a novel target for melanoma.
    Oncogene. 2019 Jan 23. pii: 10.1038/s41388-018-0640.
    PubMed     Text format     Abstract available


  8. VITIELLO M, Evangelista M, Di Lascio N, Kusmic C, et al
    Antitumoral effects of attenuated Listeria monocytogenes in a genetically engineered mouse model of melanoma.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0681.
    PubMed     Text format     Abstract available


  9. BAGATI A, Moparthy S, Fink EE, Bianchi-Smiraglia A, et al
    KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Oncogene. 2019 Jan 21. pii: 10.1038/s41388-019-0689.
    PubMed     Text format     Abstract available


  10. KUMAR R, Njauw CN, Reddy BY, Ji Z, et al
    Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma.
    Oncogene. 2019 Jan 16. pii: 10.1038/s41388-018-0632.
    PubMed     Text format     Abstract available


  11. STIEGLITZ D, Lamm S, Braig S, Feuerer L, et al
    BMP6-induced modulation of the tumor micro-milieu.
    Oncogene. 2019;38:609-621.
    PubMed     Text format     Abstract available


    November 2018
  12. RENZIEHAUSEN A, Wang H, Rao B, Weir L, et al
    The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0563.
    PubMed     Text format     Abstract available


  13. ARAFEH R, Di Pizio A, Elkahloun AG, Dym O, et al
    RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma.
    Oncogene. 2018 Nov 26. pii: 10.1038/s41388-018-0578.
    PubMed     Text format    


  14. WEI CY, Zhu MX, Lu NH, Peng R, et al
    Bioinformatics-based analysis reveals elevated MFSD12 as a key promoter of cell proliferation and a potential therapeutic target in melanoma.
    Oncogene. 2018 Nov 1. pii: 10.1038/s41388-018-0531.
    PubMed     Text format     Abstract available


    September 2018
  15. TURNER JA, Bemis JGT, Bagby SM, Capasso A, et al
    BRAF fusions identified in melanomas have variable treatment responses and phenotypes.
    Oncogene. 2018 Sep 25. pii: 10.1038/s41388-018-0514.
    PubMed     Text format     Abstract available


  16. LECLERC J, Garandeau D, Pandiani C, Gaudel C, et al
    Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.
    Oncogene. 2018 Sep 25. pii: 10.1038/s41388-018-0500.
    PubMed     Text format     Abstract available


  17. KLUG LR, Bannon AE, Javidi-Sharifi N, Town A, et al
    LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma.
    Oncogene. 2018 Sep 21. pii: 10.1038/s41388-018-0508.
    PubMed     Text format     Abstract available


    August 2018
  18. MORRIS SM, Mhyre AJ, Carmack SS, Myers CH, et al
    A modified gene trap approach for improved high-throughput cancer drug discovery.
    Oncogene. 2018;37:4226-4238.
    PubMed     Text format     Abstract available


  19. KLOSE R, Adam MG, Weis EM, Moll I, et al
    Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis.
    Oncogene. 2018;37:4260-4272.
    PubMed     Text format     Abstract available


    July 2018
  20. KUNZ M, Loffler-Wirth H, Dannemann M, Willscher E, et al
    RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.
    Oncogene. 2018 Jul 11. pii: 10.1038/s41388-018-0385.
    PubMed     Text format     Abstract available


  21. CASTEJON-GRINAN M, Herraiz C, Olivares C, Jimenez-Cervantes C, et al
    cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage.
    Oncogene. 2018;37:3631-3646.
    PubMed     Text format     Abstract available


    June 2018
  22. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Text format     Abstract available


  23. PAULITTI A, Andreuzzi E, Bizzotto D, Pellicani R, et al
    The ablation of the matricellular protein EMILIN2 causes defective vascularization due to impaired EGFR-dependent IL-8 production affecting tumor growth.
    Oncogene. 2018;37:3399-3414.
    PubMed     Text format     Abstract available


    May 2018
  24. CAI H, Cho EA, Li Y, Sockler J, et al
    Melanoma protective antitumor immunity activated by catalytic DNA.
    Oncogene. 2018 May 29. pii: 10.1038/s41388-018-0306.
    PubMed     Text format     Abstract available


  25. XIAO P, Guo Y, Zhang H, Zhang X, et al
    Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-gamma production in tumor microenvironment.
    Oncogene. 2018 May 24. pii: 10.1038/s41388-018-0337.
    PubMed     Text format     Abstract available


  26. ZHU B, Tang L, Chen S, Yin C, et al
    Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.
    Oncogene. 2018 May 22. pii: 10.1038/s41388-018-0314.
    PubMed     Text format     Abstract available


    April 2018
  27. ZHANG YY, Tabataba H, Liu XY, Wang JY, et al
    ACTN4 regulates the stability of RIPK1 in melanoma.
    Oncogene. 2018 Apr 30. pii: 10.1038/s41388-018-0260.
    PubMed     Text format     Abstract available


  28. REYES-URIBE P, Adrianzen-Ruesta MP, Deng Z, Echevarria-Vargas I, et al
    Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.
    Oncogene. 2018 Apr 26. pii: 10.1038/s41388-018-0247.
    PubMed     Text format     Abstract available


    March 2018
  29. ZUO Q, Liu J, Huang L, Qin Y, et al
    AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.
    Oncogene. 2018 Mar 19. pii: 10.1038/s41388-018-0205.
    PubMed     Text format     Abstract available


  30. MISKOLCZI Z, Smith MP, Rowling EJ, Ferguson J, et al
    Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing.
    Oncogene. 2018 Mar 16. pii: 10.1038/s41388-018-0209.
    PubMed     Text format     Abstract available


  31. LI K, Zhang TT, Wang F, Cui B, et al
    Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression.
    Oncogene. 2018 Mar 9. pii: 10.1038/s41388-018-0172.
    PubMed     Text format     Abstract available


  32. YANG JB, Zhao ZB, Liu QZ, Hu TD, et al
    FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages.
    Oncogene. 2018;37:1192-1204.
    PubMed     Text format     Abstract available


    February 2018
  33. TUSA I, Gagliardi S, Tubita A, Pandolfi S, et al
    ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
    Oncogene. 2018 Feb 27. pii: 10.1038/s41388-018-0164.
    PubMed     Text format     Abstract available


  34. YU Y, Dai M, Lu A, Yu E, et al
    PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.
    Oncogene. 2018 Feb 2. pii: 10.1038/s41388-017-0061.
    PubMed     Text format     Abstract available


    October 2017
  35. ARAIZA-OLIVERA D, Feng Y, Semenova G, Prudnikova TY, et al
    Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  36. DIETRICH P, Kuphal S, Spruss T, Hellerbrand C, et al
    Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.
    Oncogene. 2017 Oct 23. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  37. GELATO KA, Schockel L, Klingbeil O, Ruckert T, et al
    Super-enhancers define a proliferative PGC-1alpha-expressing melanoma subgroup sensitive to BET inhibition.
    Oncogene. 2017 Oct 9. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    September 2017
  38. KIM KJ, Kwon SH, Yun JH, Jeong HS, et al
    STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression.
    Oncogene. 2017;36:5445-5459.
    PubMed     Text format     Abstract available


  39. KUO TF, Chen TY, Jiang ST, Chen KW, et al
    Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway.
    Oncogene. 2017;36:5484-5496.
    PubMed     Text format     Abstract available


  40. PEREGO M, Maurer M, Wang JX, Shaffer S, et al
    A slow-cycling subpopulation of melanoma cells with highly invasive properties.
    Oncogene. 2017 Sep 18. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  41. MAURUS K, Hufnagel A, Geiger F, Graf S, et al
    The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.
    Oncogene. 2017;36:5110-5121.
    PubMed     Text format     Abstract available


    August 2017
  42. CHEN XW, Yu TJ, Zhang J, Li Y, et al
    CYP4A in tumor-associated macrophages promotes pre-metastatic niche formation and metastasis.
    Oncogene. 2017;36:5045-5057.
    PubMed     Text format     Abstract available


  43. LECLERC J, Ballotti R, Bertolotto C
    Pathways from senescence to melanoma: focus on MITF sumoylation.
    Oncogene. 2017 Aug 21. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    July 2017
  44. ZHANG W, Ding Y, Zhang C, Lu Q, et al
    Deletion of endothelial cell-specific liver kinase B1 increases angiogenesis and tumor growth via vascular endothelial growth factor.
    Oncogene. 2017;36:4277-4287.
    PubMed     Text format     Abstract available


  45. HUANG L, Wang Z, Liu C, Xu C, et al
    CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner.
    Oncogene. 2017;36:4081-4086.
    PubMed     Text format     Abstract available


    June 2017
  46. LI Y, Zhou T, Wang Y, Ning C, et al
    The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.
    Oncogene. 2017;36:3760-3771.
    PubMed     Text format     Abstract available


  47. AGAESSE G, Barbollat-Boutrand L, Sulpice E, Bhajun R, et al
    A large-scale RNAi screen identifies LCMR1 as a critical regulator of Tspan8-mediated melanoma invasion.
    Oncogene. 2017 Jun 19. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  48. DAMSKY WE, Bosenberg M
    Melanocytic nevi and melanoma: unraveling a complex relationship.
    Oncogene. 2017 Jun 12. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  49. PEREZ-ALEA M, McGrail K, Sanchez-Redondo S, Ferrer B, et al
    ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment.
    Oncogene. 2017 Jun 5. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    May 2017
  50. GIEBELER N, Schonefuss A, Landsberg J, Tuting T, et al
    Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.
    Oncogene. 2017 May 29. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    April 2017
  51. MOTZIK A, Amir E, Erlich T, Wang J, et al
    Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells.
    Oncogene. 2017 Apr 10. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  52. JAIN A, Tripathi R, Turpin CP, Wang C, et al
    Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  53. SCHAEFER SM, Segalada C, Cheng PF, Bonalli M, et al
    Sox2 is dispensable for primary melanoma and metastasis formation.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  54. CESARINI V, Guida E, Todaro F, Di Agostino S, et al
    Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
    Oncogene. 2017 Apr 3. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    March 2017
  55. ZHAI Z, Liu W, Kaur M, Luo Y, et al
    NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


  56. YANG H, Kircher DA, Kim KH, Grossmann AH, et al
    Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  57. SONG X, Hao J, Wang J, Guo C, et al
    The cancer/testis antigen MAGEC2 promotes amoeboid invasion of tumor cells by enhancing STAT3 signaling.
    Oncogene. 2017;36:1476-1486.
    PubMed     Text format     Abstract available


    February 2017
  58. LUO S, Li Y, Ma R, Liu J, et al
    Downregulation of PCK2 remodels tricarboxylic acid cycle in tumor-repopulating cells of melanoma.
    Oncogene. 2017 Feb 6. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    January 2017
  59. JEONG M, Lee EW, Seong D, Seo J, et al
    USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability.
    Oncogene. 2017;36:458-470.
    PubMed     Text format     Abstract available


  60. DOUDICAN NA, Orlow SJ
    Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
    Oncogene. 2017;36:423-428.
    PubMed     Text format     Abstract available


  61. BROWN K, Yang P, Salvador D, Kulikauskas R, et al
    WNT/beta-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  62. WORRALL C, Suleymanova N, Crudden C, Trocoli Drakensjo I, et al
    Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  63. DELYON J, Servy A, Laugier F, Andre J, et al
    PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  64. KIM HS, Jung M, Kang HN, Kim H, et al
    Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Oncogene. 2017 Jan 16. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  65. RIVERSO M, Montagnani V, Stecca B
    KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth.
    Oncogene. 2017 Jan 9. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


  66. BIANCHI-SMIRAGLIA A, Bagati A, Fink EE, Moparthy S, et al
    Microphthalmia-associated transcription factor suppresses invasion by reducing intracellular GTP pools.
    Oncogene. 2017;36:84-96.
    PubMed     Text format     Abstract available


    November 2016
  67. WANG Y, Ou Z, Sun Y, Yeh S, et al
    Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals.
    Oncogene. 2016 Nov 21. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


    October 2016
  68. FAIAO-FLORES F, Alves-Fernandes DK, Pennacchi PC, Sandri S, et al
    Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
    Oncogene. 2016 Oct 17. doi: 10.1038/onc.2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: